| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 10724 | 2021 |
| Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents Y Shaked, E Henke, JML Roodhart, P Mancuso, MHG Langenberg, ... Cancer cell 14 (3), 263-273, 2008 | 527 | 2008 |
| Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity Y Shaked, U Emmenegger, S Man, D Cervi, F Bertolini, Y Ben-David, ... Blood 106 (9), 3058-3061, 2005 | 323 | 2005 |
| Haemophagocytic syndromes in adults: current concepts and challenges ahead U Emmenegger, DJ Schaer, C Larroche, KA Neftel Swiss medical weekly 135 (2122), 299-314, 2005 | 269 | 2005 |
| Abiraterone and olaparib for metastatic castration-resistant prostate cancer NW Clarke, AJ Armstrong, A Thiery-Vuillemin, M Oya, N Shore, E Loredo, ... NEJM evidence 1 (9), EVIDoa2200043, 2022 | 219 | 2022 |
| Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies G Bocci, S Man, SK Green, G Francia, JML Ebos, JM Du Manoir, ... Cancer research 64 (18), 6616-6625, 2004 | 215 | 2004 |
| Low-dose metronomic chemotherapy: a systematic literature analysis K Lien, S Georgsdottir, L Sivanathan, K Chan, U Emmenegger European Journal of Cancer 49 (16), 3387-3395, 2013 | 213 | 2013 |
| A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose … U Emmenegger, S Man, Y Shaked, G Francia, JW Wong, DJ Hicklin, ... Cancer research 64 (11), 3994-4000, 2004 | 201 | 2004 |
| Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes U Emmenegger, U Frey, A Reimers, C Fux, D Semela, P Cottagnoud, ... American journal of hematology 68 (1), 4-10, 2001 | 189 | 2001 |
| Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts JM du Manoir, G Francia, S Man, M Mossoba, JA Medin, A Viloria-Petit, ... Clinical Cancer Research 12 (3), 904-916, 2006 | 182 | 2006 |
| Targeted anti–vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia M Franco, S Man, L Chen, U Emmenegger, Y Shaked, AM Cheung, ... Cancer research 66 (7), 3639-3648, 2006 | 174 | 2006 |
| Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy Y Shaked, U Emmenegger, G Francia, L Chen, CR Lee, S Man, ... Cancer research 65 (16), 7045-7051, 2005 | 160 | 2005 |
| Cyclophosphamide-methotrexate ‘metronomic’chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation G Bocci, M Tuccori, U Emmenegger, V Liguori, A Falcone, RS Kerbel, ... Annals of oncology 16 (8), 1243-1252, 2005 | 150 | 2005 |
| miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1 X Huang, S Taeb, S Jahangiri, U Emmenegger, E Tran, J Bruce, A Mesci, ... Cancer research 73 (23), 6972-6986, 2013 | 148 | 2013 |
| Rucaparib or physician’s choice in metastatic prostate cancer K Fizazi, JM Piulats, MN Reaume, P Ostler, R McDermott, JR Gingerich, ... New England Journal of Medicine 388 (8), 719-732, 2023 | 146 | 2023 |
| Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation U Emmenegger, A Reimers, U Frey, CH Fux, F Bihl, D Semela, ... Swiss medical weekly 132 (17/18), 230-236, 2002 | 133 | 2002 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 124 | 2022 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 112 | 2023 |
| Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy R Munoz, Y Shaked, F Bertolini, U Emmenegger, S Man, RS Kerbel The Breast 14 (6), 466-479, 2005 | 112 | 2005 |
| Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy R Yap, D Veliceasa, U Emmenegger, RS Kerbel, LM McKay, J Henkin, ... Clinical cancer research 11 (18), 6678-6685, 2005 | 106 | 2005 |
